ClinTrial Refer Melanoma App
22 January 2015
Melanoma Institute Australia has launched a new smartphone app called ClinTrial Refer Melanoma to help busy clinicians find clinical trials for their melanoma patients.
Everyone wants to find the best possible option for patients but doing detailed research for each patient is just not practical. ClinTrial Refer Melanoma helps solve this problem by keeping a quick, easy-to-use filtering app right in your pocket. You just choose your patient’s disease stage and mutation status and tap Search to see the trials that could be a possible match for your patient. The app includes up-to-date detailed information on each trial. You can refine the search further by location, trial status and sponsor, or just tap the email icon to fire off the information to a referring doctor or the patient themselves.
The app can be downloaded for free from the AppStore and Google Play. It promises to be a useful tool for clinicians by ensuring they have easy access with all potential trial treatment options for their patient. It's also hoped that the app will increase participation in clinical trials by raising the profile of existing and new studies.
Australasian Melanoma Conference AMC2021
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
Predicting disease spread in thin melanoma
A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.
Exploring our own clinical questions through MIA's new trials initiative
MIA has recently established a new division of our Clinical Trials Program which co-ordinates and manages investigator-led multi-centre trials.
Young researchers awarded Fellowships to pursue innovative treatments for melanoma
Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.
Young researchers receive boost to develop innovative treatment for melanoma
Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.
Launch of Melanoma March 2021
Aussies urged to leave their footprint on melanoma as efforts step up to save lives from the disease.
WA Melanoma Community Forum
An evening for WA melanoma patients, carers and the wider melanoma community, where speakers will provide updates on melanoma research, treatment and support.
Olivia Vivian announced as MIA ambassador
Olivia is using her Ninja star power to shine a spotlight on melanoma prevention - in memory of her dad.
Melanoma breakthrough - neoadjuvant treatment saving lives.
Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.
Melanoma breakthrough - neoadjuvant therapy saving lives.
Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.
Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.
Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.
A message to all Australians from melanoma patient Stuart Taylor
Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate.
Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.
A Ninja Warrior legend and Olympic gymnast, Olivia knows first hand the devastating impact of melanoma.
It's 'Game On Mole' this summer!
All Australians are urged to join the fight against melanoma this summer.
Prof Richard Scolyer named Outstanding Cancer Researcher of the Year
The ground-breaking work of MIA's Co-Medical Director Prof Richard Scolyer has been recognised with NSW’s highest accolade for cancer research.
Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award
A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.
MIA researchers feature on prestigious Highly Cited Researchers 2020 List
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.
Game On Mole is back this summer!
The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.
RCPA recognition for Professor Richard Scolyer.
Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.